T2 Biosystems and Canon U.S. Life Sciences Announce Joint Collaboration to Develop Novel Test Panel to Rapidly Detect Lyme Disease

T2 Biosystems and Canon U.S. Life Sciences Announce Joint Collaboration to Develop Novel Test Panel to Rapidly Detect Lyme Disease

February 3, 2015

Collaboration Leverages T2 Biosystems' Proprietary T2MR(R) Technology and Canon's Collective Expertise to Enable Improved Diagnostics

Symbiota Names Global Crop Protection Expert Peter Innes, Ph.D. to Board of Directors

Symbiota Names Global Crop Protection Expert Peter Innes, Ph.D. to Board of Directors

February 3, 2015

CAMBRIDGE, Mass., Feb. 3, 2015 /PRNewswire/ -- Symbiota™, pioneer of plant microbiome solutions that naturally promote crop health and improve agricultural production, today announced the addition of Peter Innes, Ph.D. to its board of directors.

Moderna and Institut Pasteur Sign Strategic Research Collaboration

Moderna and Institut Pasteur Sign Strategic Research Collaboration

February 3, 2015

Research partnership will advance the development of mRNA vaccines and passive immunity therapies for infectious diseases

Acceleron Pharma to Present at Upcoming Investor Conferences in February

Acceleron Pharma to Present at Upcoming Investor Conferences in February

January 28, 2015

CAMBRIDGE, Mass., Jan 28, 2015 (BUSINESS WIRE) -- Acceleron Pharma Inc. XLRN, -1.52% a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will participate in the following upcoming investor conferences.

Event: Canaccord Genuity Rare Disease, Biopharma One-on-One Day
Date / Time: Tuesday, February 3, 2015
Location: Omni Berkshire Place Hotel, New York, N.Y.

Event: Leerink Global Healthcare Conference

BIND Therapeutics Co-Founder Publishes Nanotechnology Article in the Journal of the American Medical Association

BIND Therapeutics Co-Founder Publishes Nanotechnology Article in the Journal of the American Medical Association

January 22, 2015

− Prof. Robert S. Langer provides insight on potential for application of nanomedicine in broad therapeutic areas −

Eleven Biotherapeutics Appoints Barry Gertz, MD, PhD, and Jay S. Duker, MD, to Board of Directors

Eleven Biotherapeutics Appoints Barry Gertz, MD, PhD, and Jay S. Duker, MD, to Board of Directors

January 22, 2015

 - Leaders in Industry and Academia Join Board as Eleven’s Ocular Pipeline Advances –

Seres Health Announces Addition of Mark Wilcox, M.D. to Scientific Advisory Board

Seres Health Announces Addition of Mark Wilcox, M.D. to Scientific Advisory Board

January 21, 2015

CAMBRIDGE, Mass., Jan. 21, 2015 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, announced today the addition of Mark Wilcox, M.D., of the University of Leeds, to its Scientific Advisory Board (SAB).

Avedro Appoints Brian Roberts as Chief Financial Officer

Avedro Appoints Brian Roberts as Chief Financial Officer

January 20, 2015

 WALTHAM, Mass.--()--Avedro Inc., a Boston-based ophthalmic pharmaceutical and medical device company announced today that Brian K. Roberts is joining the company as its new Chief Financial Officer. In this position, Mr.

Report Published in The Journal of the American Medical Association Highlights Impact of T2 Biosystems' T2MR Technology in Diagnosing Infections

Report Published in The Journal of the American Medical Association Highlights Impact of T2 Biosystems' T2MR Technology in Diagnosing Infections

January 13, 2015

Paper Co-Authored by T2 Biosystems' Co-Founders Dr. Robert Langer and Dr. Ralph Weissleder Underscores Potential for T2MR Over Existing Diagnostic Methodologies

Seres Health Appoints Shelley Trucksis, Ph.D., M.D. as Executive Vice President and Chief Medical Officer

Seres Health Appoints Shelley Trucksis, Ph.D., M.D. as Executive Vice President and Chief Medical Officer

January 15, 2015

CAMBRIDGE, Mass., Jan.15, 2015 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, today announced the appointment of Michele (Shelley) Trucksis, Ph.D., M.D., as Executive Vice President and Chief Medical Officer. In this role, Dr. Trucksis will be responsible for overseeing the clinical development and operations of Seres' Ecobiotic® product pipeline.